In addition, RHOBTB2 expression was increased in AML patients without FLT3 mutation (P = 0.024, Figure 4D) and patients without PML-RAR fusion (P = 0.0038, Figure 4E). Here, RHOBTB2 is linked to acute myeloid leukemia.